Cellular hierarchies predict drug response in acute myeloid leukemia

被引：0
|
作者：
Raffel, Simon [1 ]
Velten, Lars [2 ,3 ]
Haas, Simon [4 ,5 ,6 ,7 ,8 ,9 ,10 ,11 ,12 ]
机构：
[1] Univ Hosp Heidelberg, Dept Med Hematol Oncol & Rheumatol 5, Heidelberg, Germany
[2] Barcelona Inst Sci & Technol, Ctr Genom Regulat CRG, Dr Aiguader 88, Barcelona 08003, Spain
[3] Univ Pompeu Fabra UPF, Barcelona, Spain
[4] Charite Univ Med Berlin, Berlin Inst Hlth BIH, Berlin, Germany
[5] Helmholtz Assoc, Max Delbr uck Ctr Mol Med, Berlin Inst Med Syst Biol, Berlin, Germany
[6] Charite Univ Med Berlin, Berlin, Germany
[7] Free Univ Berlin, Berlin, Germany
[8] Humboldt Univ, Dept Hematol Oncol & Canc Immunol, Berlin, Germany
[9] Heidelberg Inst Stem Cell Technol & Expt Med HI S, Heidelberg, Germany
[10] Deutsch Krebsforschungszentrum DKFZ, Div Stem Cells & Canc, Heidelberg, Germany
[11] DKFZ ZMBH Alliance, Heidelberg, Germany
[12] German Canc Consortium DKTK, Heidelberg, Germany
来源：
CANCER CELL | 2022年 / 40卷 / 09期
关键词：
STEMNESS SCORE; RISK;
D O I：
10.1016/j.ccell.2022.08.019
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：917 / 919
页数：3
相关论文
共 50 条
  • [41] Busulfan pharmacokinetics do not predict relapse in acute myeloid leukemia
    KS Baker
    B Bostrom
    T DeFor
    NKC Ramsay
    WG Woods
    BR Blazar
    Bone Marrow Transplantation, 2000, 26 : 607 - 614
  • [42] Cellular drug resistance in acute myeloid leukemia:: literature review and preliminary analysis of an ongoing collaborative study
    Kaspers, CJL
    Zwaan, CM
    Veerman, AJP
    Rots, MG
    Pieters, R
    Bucsky, P
    Domula, M
    Göbel, U
    Graf, N
    Havers, W
    Jorch, N
    Kabisch, K
    Spaar, HJ
    Ritter, J
    Creutzig, U
    KLINISCHE PADIATRIE, 1999, 211 (04): : 239 - 244
  • [43] Potential new drug for resistant acute myeloid leukemia
    Bond, Theo
    PHARMACOGENOMICS, 2013, 14 (03) : 234 - 234
  • [44] Antibody-drug conjugates in acute myeloid leukemia
    Scheinberg, DA
    Maslak, P
    Jurcic, JG
    NATURE CLINICAL PRACTICE ONCOLOGY, 2006, 3 (05): : 238 - 239
  • [45] Management and orphan drug development for acute myeloid leukemia
    Zhang, Haojian
    Li, Shaoguang
    Li, Huawei
    EXPERT OPINION ON ORPHAN DRUGS, 2014, 2 (05): : 441 - 451
  • [46] DRUG-RESISTANCE IN ACUTE MYELOID-LEUKEMIA
    BAINES, P
    LIMAYE, M
    HOY, T
    PADUA, RA
    WHITTAKER, JA
    ALSABAH, A
    BURNETT, AK
    BRITISH JOURNAL OF HAEMATOLOGY, 1993, 84 : 2 - 2
  • [47] The role of drug efflux pumps in acute myeloid leukemia
    Van Der Kolk, DM
    De Vries, EGE
    Müller, M
    Vellenga, E
    LEUKEMIA & LYMPHOMA, 2002, 43 (04) : 685 - 701
  • [48] Optimization of a Drug Screening Platform in Acute Myeloid Leukemia
    Chat, Laureen
    Pasanisi, Justine
    Pacchiardi, Kim
    Pioton, Alya
    Duchmann, Matthieu
    Itzykson, Raphael
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S232 - S232
  • [49] CMV-specific cellular therapy for acute myeloid leukemia?
    Thomson, Kirsty J.
    Mackinnon, Stephen
    Peggs, Karl S.
    BLOOD, 2012, 119 (04) : 1088 - 1090
  • [50] Cellular immunotherapy for acute myeloid leukemia: How specific should it be?
    Lee, Jong Bok
    Chen, Branson
    Vasic, Daniel
    Law, Arjun D.
    Zhang, Li
    BLOOD REVIEWS, 2019, 35 : 18 - 31
12345